Brought to you by 
Torii gets Japanese marketing rights to HIV therapy from parent Japan Tobacco
11 Jul 2016
Executive Summary
Japan Tobacco Inc. has licensed its Japanese pharma subsidiary Torii Pharmaceutical Co. Ltd. exclusive rights to market a single-tablet HIV treatment containing JTK303 (elvitegravir) in Japan.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com